Alshahawey Mona, Jafari Eissa, Smith Steven M, McDonough Caitrin W
Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States.
Department of Clinical Pharmacy, College of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
J Am Med Inform Assoc. 2024 Dec 1;31(12):2899-2907. doi: 10.1093/jamia/ocae227.
Hypertension (HTN) remains a significant public health concern and the primary modifiable risk factor for cardiovascular disease, which is the leading cause of death in the United States. We applied our validated HTN computable phenotypes within the All of Us Research Program to uncover prevalence and characteristics of HTN and apparent treatment-resistant hypertension (aTRH) in United States.
Within the All of Us Researcher Workbench, we built a retrospective cohort (January 1, 2008-July 1, 2023), identifying all adults with available age data, at least one blood pressure (BP) measurement, prescribed at least one antihypertensive medication, and with at least one SNOMED "Essential hypertension" diagnosis code.
We identified 99 461 participants with HTN who met the eligibility criteria. Following the application of our computable phenotypes, an overall population of 81 462 were further categorized to aTRH (14.4%), stable-controlled HTN (SCH) (39.5%), and Other HTN (46.1%). Compared to participants with SCH, participants with aTRH were older, more likely to be of Black or African American race, had higher levels of social deprivation, and a heightened prevalence of comorbidities such as hyperlipidemia and diabetes. Heart failure, chronic kidney disease, and diabetes were the comorbidities most strongly associated with aTRH. β-blockers were the most prescribed antihypertensive medication. At index date, the overall BP control rate was 62%.
All of Us provides a unique opportunity to characterize HTN in the United States. Consistent findings from this study with our prior research highlight the interoperability of our computable phenotypes.
高血压(HTN)仍然是一个重大的公共卫生问题,也是心血管疾病的主要可改变风险因素,而心血管疾病是美国的主要死因。我们在美国国立卫生研究院“我们所有人”研究项目中应用经过验证的高血压可计算表型,以揭示美国高血压和明显难治性高血压(aTRH)的患病率及特征。
在“我们所有人”研究者工作台中,我们建立了一个回顾性队列(2008年1月1日至2023年7月1日),识别所有有可用年龄数据、至少一次血压(BP)测量值、至少开具过一种抗高血压药物且至少有一个SNOMED“原发性高血压”诊断代码的成年人。
我们识别出99461名符合资格标准的高血压参与者。应用我们的可计算表型后,81462人的总体人群被进一步分类为aTRH(14.4%)、稳定控制的高血压(SCH)(39.5%)和其他高血压(46.1%)。与SCH参与者相比,aTRH参与者年龄更大,更可能是黑人或非裔美国人,社会剥夺水平更高,高脂血症和糖尿病等合并症的患病率更高。心力衰竭、慢性肾脏病和糖尿病是与aTRH关联最密切的合并症。β受体阻滞剂是最常开具的抗高血压药物。在索引日期,总体血压控制率为62%。
“我们所有人”研究项目提供了一个独特的机会来描述美国的高血压情况。本研究与我们之前研究的一致发现突出了我们可计算表型的互操作性。